NRP104

Known as: NRP 104, NRP-104 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2017
0120062017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant used for the treatment of attention-deficit/hyperactivity… (More)
Is this relevant?
Review
2014
Review
2014
BACKGROUND Here we review the safety and tolerability profile of lisdexamfetamine dimesylate (LDX), the first long-acting prodrug… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2012
2012
To examine the efficacy of lisdexamfetamine dimesylate (LDX) in adults with attention-deficit/hyperactivity disorder (ADHD) who… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Review
2009
Review
2009
OBJECTIVE To review the pharmacology, pharmacokinetics, efficacy, and safety of the prodrug lisdexamfetamine for the treatment of… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Lisdexamfetamme dimesylate (LDX) is a therapeutically inactive amphetamine prodrug. It was developed with the goal of… (More)
Is this relevant?
2007
2007
Background: Lisdexamfetamine dimesylate (LDX) is a therapeutically inactive amphetamine prodrug. It was developed with the goal… (More)
  • table I
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2006
Review
2006
Initiatives to develop better-tolerated, more efficacious pharmacological agents with improved drug delivery systems have driven… (More)
Is this relevant?